Press Releases

InVivo Therapeutics Announces University of California San Diego Medical Center as New Site for INSPIRE Study

Published: February 3, 2016

CAMBRIDGE, Mass. (Feb 3, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that University of California (UC), San Diego Medical Center has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. UC San Diego Medical Center, located in Hillcrest, has 390 beds and is one of only two Level I Trauma Centers in San Diego County. Joseph Ciacci, M.D., Clinical Professor of Surgery at the UC San Diego School of Medicine and Chief of […]

View Article
InVivo Therapeutics to Present at 8th Annual Biotech Showcase

Published: January 5, 2016

CAMBRIDGE, Mass. (Jan 5, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual Biotech Showcase to be held January 11-13, 2016 in San Francisco, CA. The company’s presentation will be Monday, January 11 at 3:30 PM (PST). A live webcast will be available at http://edge.media-server.com/m/p/om4nkdg5, and a webcast replay will be available at the same address approximately 2 hours after the live webcast presentation. Mr. Perrin said, “I’m pleased to be presenting at the Biotech Showcase and to have the opportunity to highlight the progress […]

View Article
InVivo Therapeutics Announces Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the Neuro-Spinal Scaffold™

Published: January 4, 2016

CAMBRIDGE, Mass. (Jan 4, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) announced that it has received approval of a protocol amendment from the U.S. Food and Drug Administration (FDA) that will convert its ongoing pilot study into a pivotal probable benefit study. Prior to this announcement, the approval was conditional solely upon a minor change to the informed consent form. With this transition, the study will be known formally as “The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.” The INSPIRE Study is […]

View Article
InVivo Therapeutics Announces Conditional Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the Neuro-Spinal ScaffoldTM

Published: December 3, 2015

CAMBRIDGE, Mass. (Dec 3, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) announced it has received conditional approval of a study protocol amendment from the U.S. Food and Drug Administration (FDA) that will convert its ongoing pilot study into a pivotal probable benefit study. The approval is conditional solely upon a minor change to the informed consent form that has already been submitted to the FDA. Full approval of the amendment is expected in the next 30 days. With this transition, the study will be known formally as “The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal ScaffoldTM for Safety […]

View Article
InVivo Therapeutics Announces Bioengineered Neural TrailsTM Program for Chronic Spinal Cord Injury

Published: December 2, 2015

New Intellectual Property to Support Minimally Invasive Transplantation of Trails of Neural Stem Cells – Executed Agreements with University of California, San Diego and Dr. James Guest – – InVivo Provisional Patent Application Filed – CAMBRIDGE, Mass. (Dec 2, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced an innovative strategy for the treatment of chronic spinal cord injury (SCI). The company will focus its research efforts for chronic SCI on Bioengineered Neural TrailsTM. Bioengineered Neural Trails are injectable combinations of biomaterials and neural stem cells (NSCs) delivered using minimally-invasive surgical instrumentation and techniques to create trails across the chronic […]

View Article
InVivo Therapeutics Announces Key Opinion Leader Event and Company Update with Robert Langer, ScD, and Nicholas Theodore, MD

Published: December 1, 2015

CAMBRIDGE, Mass. (Dec 1, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the company will host a Key Opinion Leader (KOL) Event and Company Update in New York on Thursday, December 3 from 5-7PM ET. The meeting will feature presentations by two renowned key opinion leaders: Bob Langer, ScD, the David H. Koch Institute Professor at Massachusetts Institute of Technology and co-founder of InVivo; and Nick Theodore, MD, Chief of Spinal Surgery at the Barrow Neurosurgical Institute and the neurosurgeon who performed the first i. Neuro-Spinal ScaffoldTM implantation. Dr. Langer will discuss his contributions to the development of the field […]

View Article
InVivo Therapeutics Announces Jay Blackington as New Vice President, Head of Human Resources

Published: November 25, 2015

CAMBRIDGE, Mass. (Nov 25, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Jay Blackington as Vice President, Head of Human Resources. Mr. Blackington most recently was Senior Vice President, Global Human Resources at the Avid Corporation, a leading global provider of digital media content-creation products and solutions for audio, film, video, and broadcast professionals. Before Avid, Mr. Blackington served for nine years as Vice President, Global Human Resources at EMC2, an industry-leading global cloud computing and big data IT provider with 50,000 employees. While at EMC2, he held several leadership positions and most recently provided the HR […]

View Article
InVivo Therapeutics Reports 2015 Third Quarter Financial Results and Business Update

Published: November 4, 2015

CAMBRIDGE, Mass. (November 4, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended September 30, 2015. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We continued to make substantive and fundamental progress at InVivo through the third quarter and communicated our advancements through several media, scientific, and medical outlets. We enrolled the last two patients of the planned five-patient pilot study and announced an AIS conversion in the third patient with a high thoracic injury at one month, which occurs less than four percent of the time. We also announced plans to transition […]

View Article
InVivo Therapeutics Reports Significant Improvement of First Patient Implanted with Neuro-Spinal Scaffold™

Published: October 23, 2015

CAMBRIDGE, Mass. (Oct 23, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced a 12- month post-implant update for the first study patient in the company’s ongoing pilot trial of its investigational Neuro-Spinal ScaffoldTM in patients with complete acute spinal cord injury. In the time between the 6-month and 12-month post-injury assessments, the patient continued to demonstrate improvement in the American Spinal Injury Association (ASIA) lower extremity motor score with an additional 8 points gained on this 50 point score. The patient demonstrated additional bilateral improvements in the motor function of hip flexors and knee extensors and for the first […]

View Article
InVivo Therapeutics Receives SEC Notice of Closing of Inquiry

Published: October 22, 2015

CAMBRIDGE, Mass. (Oct 22, 2015) – InVivo Therapeutics Holdings Corp. (NVIV) today announced it has received written notification from the Securities and Exchange Commission (SEC) that it has concluded its investigation of the Company, which, as the Company previously disclosed, sought information concerning statements related to the timing and completion of the clinical study of the Neuro-Spinal ScaffoldTM. The SEC said that it does not intend to recommend an enforcement action against the Company. About the Neuro-Spinal ScaffoldTM Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.